Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Genes Brain Behav. 2016 Oct 21;16(3):342–351. doi: 10.1111/gbb.12343

Figure 4.

Figure 4

Intra-orbitofrontal cortex M100907 does not attenuate a probabilistic reversal learning deficit, but increases perseveration in BTBR mice. The treatments on the x-axis represent the treatment received prior to reversal learning. Mice did not receive infusions before acquisition. A) Mean (±SEM) trials to criterion on acquisition and reversal learning. This test included the following groups: B6: vehicle (n = 9); BTBR: vehicle (n = 8), 0.2μg (n = 6), 0.6μg (n = 7). Vehicle-treated BTBR mice required significantly more reversal learning trials compared with that of B6 vehicle-treated mice. M100907 at 0.2μg or 0.6μg infused into the orbitofrontal cortex did not affect trials to criterion. *p < 0.01 vs. B6-vehicle. B) Mean (±SEM) perseverative and regressive errors committed during reversal learning. Infusions of M100907 at 0.2μg and 0.6μg into the orbitofrontal cortex significantly increased perseverative errors committed by BTBR mice compared to vehicle treated BTBR mice. B6: vehicle (n = 9); BTBR: vehicle (n = 9); 0.2μg (n = 8); 0.6μg (n = 7). *p < 0.05 vs. B6-vehicle; #p < 0.05, **p < 0.01 vs. B6-vehicle; ##p < 0.01 vs. BTBR-vehicle. Vehicle-treated BTBR mice made significantly more regressive errors compared to vehicle-treated B6 mice. Microinfusions of M100907 at 0.2μg or 0.6μg into the orbitofrontal cortex did not attenuate regressive errors in BTBR mice compared to vehicle-treated BTBR mice. *p < 0.05 vs. B6-vehicle.